Cancer agents and Electrolyte Disorders

 • Hypocalcemia: Cisplatin from Low Mg, Cetuximab- due to low Mg

Axitinib, Regorafenib 

 • Hypophosphatemia: Ifosfamide - Fanconi syndrome, Imatinib- Secondary Pth, BRAF inhibitors, Sorafenib- vit D mediated, Regorafenib

 • Hypomaqnesemia: Cisplatin- renal losses, Cetuximab and Panitumumab- renal wasting, Erlotinib, Trastuzumab

 • Hyponatremia: Cisplatin- renal salt wasting, Bevacizumab, Volociximab-SIADH, Temsirolimus and everolimus- Aldosterone resistance, PD-1 Inhibitors- unknown mechanism, CTLA-4 inhibitors- hypophysitis, Methotrexate- SIADH, Trastuzumab

 • Hypokalemia: Cisplatin- due to low Mg, Ifosfamide - Fanconi syndrome, Cetuximab- due to low Mg, BRAF inhibitors- fanconi, Methotrexate - ion channel dysfunction,  Vandetanib



Dr. Kenar Jhaveri @kdjhaveri



#Electrolytes #Disorders #Cancer #agents #chemotherapy #diagnosis #differential